CHOP-21方案用于实体器官移植后移植后淋巴细胞增殖性疾病（PTLD）的治疗。
CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.
作者信息
Choquet Sylvain, Trappe Ralf, Leblond Veronique, Jäger Ulrich, Davi Frederic, Oertel Stephan
出版信息
Haematologica. 2007 Feb;92(2):273-4. doi: 10.3324/haematol.10595.
There is no definitive treatment for post-transplant lymphoproliferative disorder (PTLD) that does not respond to reduction of immunosuppression. With a median follow-up of 8.8 years, the current retrospective analysis of standard CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) in 26 adults with PTLD demonstrated an overall response rate of 65% and median overall and progression-free survivals of 13.9 and 42 months, respectively.
对于对免疫抑制减量无反应的移植后淋巴细胞增殖性疾病（PTLD），尚无确切的治疗方法。在中位随访8.8年的情况下，目前对26例患有PTLD的成人进行标准CHOP（环磷酰胺、阿霉素、长春新碱和泼尼松）治疗的回顾性分析显示，总缓解率为65%，中位总生存期和无进展生存期分别为13.9个月和42个月。
Zotero 插件